The opposition was filed in May 2023 with the European Patent Office (EPO) by bioMerieux and a strawman representing other undisclosed firm (s) against T2 Biosystems’ granted European Patent No. 3 443 ...
European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver diseaseApproval follows posit ...